US FDA Touts Big Improvements In Product Review Process: Report
The US agency says it has either met or exceeded all its 2018-2020 strategic priorities, including simplifying core processes in its product review pathways.
You may also be interested in...
Center for Devices and Radiological Health director Jeff Shuren said on 22 July that the center is incorporating lessons learned from the COVID-19 pandemic and its ongoing user-fee negotiations with industry into its upcoming set of strategic goals.
A Chat With Jeff Shuren: FDA Device Center Chief Worries About Agency Staffing; Talks MDUFA V, Pandemic, More
The head of the US agency’s device center spoke with Medtech Insight in an exclusive wide-ranging interview about his priorities for the future, the nuances of the MDUFA V user-fee negotiations, how COVID-19 has changed the agency, and more.
This is MDIC’s third collaborative community, following groups for the US FDA’s Case for Quality and health technology.